Compare ESOA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESOA | ENTX |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.2M | 142.0M |
| IPO Year | 2006 | 2018 |
| Metric | ESOA | ENTX |
|---|---|---|
| Price | $7.93 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $21.00 | $10.00 |
| AVG Volume (30 Days) | ★ 186.3K | 85.0K |
| Earning Date | 02-09-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $411,001,373.00 | $124,000.00 |
| Revenue This Year | $0.24 | N/A |
| Revenue Next Year | $8.00 | N/A |
| P/E Ratio | $406.50 | ★ N/A |
| Revenue Growth | 16.80 | ★ 25.25 |
| 52 Week Low | $7.64 | $1.50 |
| 52 Week High | $17.16 | $3.22 |
| Indicator | ESOA | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.48 | 30.33 |
| Support Level | $8.25 | $2.07 |
| Resistance Level | $8.95 | $2.22 |
| Average True Range (ATR) | 0.46 | 0.15 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 6.77 | 11.49 |
Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.